Provided is a monoclonal antibody that has specificity affinity for CD20. It can be a special property combination of CD20 antigen molecules, so as to single-minded kill B lymphoma cells.
Figure 1 OFA-opsonized B cells bind more C1q than RTX-opsonized B cells.
A and B, Varying amounts of C1q were added to B cells suspended in complete RPMI 1640 medium and then reacted with either Al647 OFA, Al647 RTX, or Al647 7D8-IgG4 (K322A). C, Binding of C1q to CLL cells opsonized with either OFA or with RTX, similar conditions and analyses. D-I, Cells were combined in cold medium with Al647 mAb and varying amounts of C1q and then incubated at 37°C. Aliquots were removed at the indicated times, quenched with ice-cold BSA-PBS, washed, probed with FITC anti-C1q, and then analyzed by flow cytometry for C1q binding (D-F) and mAb binding (G-I). D and G, Raji cells. E and H, Daudi cells. F and I, Z138 cells.
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G., Parren, P. W., & Taylor, R. P. (2009). Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. The Journal of Immunology, 183(1), 749-758.
Figure 2 C1q colocalizes with bound OFA on Daudi cells.
A, Fluorescence intensity of Al488 C1q and Al647 mAbs bound to Daudi cells. Very little C1q binding to RTX- or 7D8-IgG4 (K322A)-opsonized cells was observed. B and C, Fluorescence signals for Al647 OFA-opsonized samples were analyzed for colocalization with bound Al488 C1q.
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G., Parren, P. W., & Taylor, R. P. (2009). Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. The Journal of Immunology, 183(1), 749-758.
Figure 3 OFA-opsonized cells are killed more effectively in C1q depleted serum supplemented with low C1q concentrations than are RTX opsonized cells.
A, Daudi cells were combined with OFA, RTX, or with no mAb in 50% C1q-depleted NHS supplemented with varying amounts of C1q. B and C, In the presence of C1q, OFA-opsonized cells are killed very rapidly. OFA-opsonized Raji (B) or Z138 (C)cells were incubated at 37°C for 1-20 min in 50% C1q-depleted NHS supplemented with 1, 2, or 35 μg/ml C1q. D and E, In C1q-depleted NHS supplemented with either 35 or 1 μg/ml C1q, binding of C1q to OFA opsonized Raji or Z138 cells is quite weak.
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G., Parren, P. W., & Taylor, R. P. (2009). Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. The Journal of Immunology, 183(1), 749-758.
Figure 4 In C1q-depleted serum supplemented with limited amounts of C1q, OFA-opsonized Raji cells have higher levels of C3b deposition and undergo greater CDC than do RTX-opsonized Raji cells.
A, In medium, OFA-opsonized Raji cells bind more C1q than do RTX-opsonized cells. B and C, C3b deposition and CDC as a function of time and C1q concentration.
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G., Parren, P. W., & Taylor, R. P. (2009). Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. The Journal of Immunology, 183(1), 749-758.
Figure 5 In C1q-depleted serum supplemented with limited amounts of C1q, OFA-opsonized Daudi cells have higher levels of C3b deposition and undergo greater CDC than do RTX-opsonized Daudi cells.
A, In medium, OFA-opsonized Daudi cells bind more C1q than do RTX-opsonized cells. B and C, C3b deposition and CDC as a function of time and C1q concentration.
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G., Parren, P. W., & Taylor, R. P. (2009). Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. The Journal of Immunology, 183(1), 749-758.
Figure 6 In C1q-depleted serum supplemented with limited amounts of C1q, OFA-opsonized Z138 cells have higher levels of C3b deposition and undergo greater CDC than do RTX-opsonized Z138 cells.
A, In medium, OFA-opsonized Z138 cells bind more C1q than do RTX-opsonized cells. B and C, C3b deposition and CDC as a function of time and C1q concentration.
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G., Parren, P. W., & Taylor, R. P. (2009). Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. The Journal of Immunology, 183(1), 749-758.
Figure 7 In C1q-depleted serum supplemented with limited amounts of C1q, primary CLL cells opsonized with OFA bind more C1q than cells opsonized with RTX, have higher levels of C3b deposition, and have more CDC.
A-C, Dose-response profile for CLL cells from one CLL patient. D, Results for C1q binding in medium, and C3b deposition and CDC in C1qdepleted serum (35 μg/ml C1q for all cases) for CLL cells from seven patients.
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G., Parren, P. W., & Taylor, R. P. (2009). Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. The Journal of Immunology, 183(1), 749-758.
Figure 8 OFA induces greater cell kill through CDC compared with RTX.
OFA demonstrated much greater cell kill by CDC than by RTX, with 20 mg/ml eliciting high levels of cell death in all cytogenetic groups. Statistical analysis revealed that, when compared with RTX, OFA induced significantly more CDCmediated cell death in 11q - and 17p- cohorts, with borderline significant effect in the normal/13q group
Middleton, O., Cosimo, E., Dobbin, E., McCaig, A. M., Clarke, C., Brant, A. M., ... & Wheadon, H. (2015). Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia, 29(1), 107-114.
Figure 9 Binding stability of CD20 mAbs to human lymphoma B cell lines.
Binding of 60 nM Ofatumumab (OFA), Rituximab (RTX), or Obinutuzumab (OBI) to Daudi (A), Ramos (B), LCL1.11 (C), or P493.6 (D) cells was recorded until equilibrium was approached (not shown) followed by measurement of mAb dissociation either in plain cell culture medium or in presence of 60 nM of the respective unlabeled (unlab.) antibody. For all cell lines the dissociation of OFA was measured in presence of 180 nM unlabeled OFA (instead of 60 nM) to enhance possible cell-line differences. (E) Signal intensities were normalized to 100% at the beginning of the dissociation. The remaining signal after 1 h (black) and 2 h (gray) dissociation both in plain media (solid) and in presence of unlabeled antibody (shaded) are plotted for human B cell lines.
Bondza, S., Marosan, A., Kara, S., Lösing, J., Peipp, M., Nimmerjahn, F., ... & Lux, A. (2021). Complement-dependent activity of CD20-specific IgG correlates with bivalent antigen binding and C1q binding strength. Frontiers in immunology, 11, 609941.
Figure 10 Binding stability of CD20 mAbs to human primary B cells.
Binding of 60 nM Ofatumumab (OFA), Rituximab (RTX) or Obinutuzumab (OBI) to primary human B cells isolated from blood of healthy donors was recorded until equilibrium was approached (not shown) and then mAb dissociation was measured either in plain cell culture medium or in presence of 60 nM of the respective unlabeled antibody. (A) One out of three independent measurements shown. (B) Signal intensities were normalized to 100% at the beginning of the dissociation. The remaining signal after 1 h (black) and 2 h (gray) dissociation both in plain media (solid) and in presence of unlabeled antibody (shaded) are plotted.
Bondza, S., Marosan, A., Kara, S., Lösing, J., Peipp, M., Nimmerjahn, F., ... & Lux, A. (2021). Complement-dependent activity of CD20-specific IgG correlates with bivalent antigen binding and C1q binding strength. Frontiers in immunology, 11, 609941.
Figure 11 Correlative studies on patients for the first 30 days of the trial.
OFA was infused on days 1, 8 and 29. Blood samples were obtained immediately before, and 2, 6 and 24 hrs after starting OFA infusions. Results are normalized to pre-treatment values for absolute lymphocyte counts (ALC), CD20, and CH50. Bound OFA is normalized to the 2 hr mark (first infusion), usually the maximum amount bound; values for bound C3d are normalized to maximum amount bound, observed at 2 or 6 hrs. Absolute values for these parameters are provided in Table I, along with representative uncertainties (SD). A. ALC; B. B cell surface levels of CD20; C. cell-bound OFA; D. complement titers (CH50 determinations); E. C3d deposition on B cells. The complement titer of patient N1 was low throughout the study and is not plotted in panel D. Results in B, C and E are based on duplicate determinations; CH50 titers were determined in triplicate.
Beurskens, F. J., Lindorfer, M. A., Farooqui, M., Beum, P. V., Engelberts, P., Mackus, W. J., ... & Taylor, R. P. (2012). Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. The Journal of Immunology, 188(7), 3532-3541.
Figure 12 The Serum Ofatumumab (OFA) Level at 8 Hours After Starting Therapy is Inversely Proportional to the Total Pre-treatment Cell Associated Circulating CD20 and the Decrease in this Value after the Initial Dose of 300 mg of OFA.
These correlations showed that 8hr OFA levels were inversely correlated with pre-treatment total cell-associated CD20 and with the change in the total cellassociated CD20 between the 0 hr and 8 hr specimens.
Baig, N. A., Taylor, R. P., Lindorfer, M. A., Church, A. K., LaPlant, B. R., Pettinger, A. M., ... & Zent, C. S. (2014). Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. The Journal of Immunology, 192(4), 1620-1629.
Figure 13 Levels of Ofatumumab (OFA) Binding to CLL Cells Equivalent to Those Measured in Circulating CLL Cells After Initiation of OFA Therapy Have Low in Vitro Complement Activating Activity.
There was a progressive increase in OFA binding as the OFA concentration was increased from 0.025 μg/ml to 0.100 μg/ml.
Baig, N. A., Taylor, R. P., Lindorfer, M. A., Church, A. K., LaPlant, B. R., Pettinger, A. M., ... & Zent, C. S. (2014). Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. The Journal of Immunology, 192(4), 1620-1629.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-913-sdAb | Recombinant Anti-human MS4A1 VHH Single Domain Antibody | IP, FC, ChiP, Neut | Llama VHH |
HPAB-M0704-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone 2HCD25) | ELISA, FuncS | Camelid VHH |
HPAB-M0705-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone 2HCD16) | ELISA | Camelid VHH |
HPAB-M0706-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone R3CD7) | ELISA | Camelid VHH |
HPAB-M0707-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone 2HCD78) | ELISA | Camelid VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-133 | Anti-Human CD20 Recombinant Antibody (Afutuzumab) | IP, IF, FuncS, FC, Neut, ELISA, ICC | IgG3 - kappa |
TAB-1635CL | Anti-Human MS4A1 Recombinant Antibody (BVX20) | Inhib | Humanized antibody |
TAB-1636CL | Human Anti-MS4A1 Recombinant Antibody (TAB-1636CL) | ADCC, CDC | Humanized IgG |
TAB-1637CL | Human Anti-MS4A1 Recombinant Antibody (TAB-1637CL) | ADCC, CDC | Humanized IgG |
TAB-1638CL | Human Anti-MS4A1 Recombinant Antibody (TAB-1638CL) | ADCC, CDC | Humanized IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
PABW-019 | Human Anti-MS4A1 Recombinant Antibody (clone C2H7) | WB, IF, FuncS | Chimeric (mouse/human) IgG |
FAMAB-0144-CN | Human Anti-MS4A1 Recombinant Antibody (clone C2B8) | WB, ELISA | Chimeric (mouse/human) IgG1 |
HPAB-0742-CN | Human Anti-MS4A1 Recombinant Antibody (HPAB-0742-CN) | ELISA, FC | Human IgG |
HPAB-0743-CN | Human Anti-MS4A1 Recombinant Antibody (HPAB-0743-CN) | ELISA, FC | Human IgG |
HPAB-0744-CN | Human Anti-MS4A1 Recombinant Antibody (HPAB-0744-CN) | ELISA, FC | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-419 | Human Anti-MS4A1 Recombinant Antibody (clone 2F2); Fab Fragment | WB, ELISA, FuncS | Human Fab |
PFBL-420 | Mouse Anti-MS4A1 Recombinant Antibody (clone GA101); Fab Fragment | WB, ELISA, FuncS | Mouse Fab |
HPAB-0018-FY-F(E) | Human Anti-MS4A1 Recombinant Antibody; Fab Fragment (HPAB-0018-FY-F(E)) | FC | Humanized Fab |
HPAB-0021-FY-F(E) | Human Anti-MS4A1 Recombinant Antibody (clone hu3D9); Fab Fragment | FC | Humanized Fab |
HPAB-0819-CN-F(E) | Human Anti-MS4A1 Recombinant Antibody (clone 1F5RKF12); Fab Fragment | ELISA, FC | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0001CL | Human Anti-MS4A1 Recombinant Antibody (TAB-0001CL) | ELISA, ADCC, CDC | Human IgG |
TAB-1703CL-F(E) | Human Anti-MS4A1 Recombinant Antibody; Fab Fragment (TAB-1703CL-F(E)) | FC, CDC, IP | Human Fab |
TAB-1704CL-F(E) | Human Anti-MS4A1 Recombinant Antibody; Fab Fragment (TAB-1704CL-F(E)) | IP | Human Fab |
PABX-028 | Recombinant Human Anti-CD20 Antibody (Ofatumumab) | WB, ELISA, IF, FuncS, Apop, BA | IgG |
PABX-028-F (E) | Recombinant Human Anti-CD20 Antibody Fab Fragment (Ofatumumab) | WB, ELISA, IF, FuncS | Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1632CL-S(P) | Anti-Human MS4A1 Recombinant Antibody scFv Fragment (1F5) | FC | |
TAB-1657CL-F(E) | Anti-Human MS4A1 Recombinant Antibody Fab Fragment (1K1422) | Apop, FuncS | |
TAB-1658CL-F(E) | Anti-Human MS4A1 Recombinant Antibody Fab Fragment (1K1791) | Apop, FuncS | |
PABX-026-S (P) | Recombinant Mouse Anti-CD20 Antibody scFv Fragment (C2H7) | WB, ELISA, FuncS | scFv |
PABX-028-S (P) | Recombinant Human Anti-CD20 Antibody scFv Fragment (Ofatumumab) | WB, ELISA, IF, FuncS | scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1665CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1665CL-S(P)) | CDC | Mouse scFv |
TAB-1666CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1666CL-S(P)) | CDC | Mouse scFv |
TAB-1667CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1667CL-S(P)) | CDC | Mouse scFv |
TAB-1668CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1668CL-S(P)) | CDC | Mouse scFv |
TAB-1669CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1669CL-S(P)) | CDC | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-115LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation) | ELISA | Humanized antibody |
Gly-134LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-135LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-136LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-137LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-134LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-135LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-136LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-137LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-138LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-142LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-155LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/High-mannose glycosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-171LC | Recombinant Anti-Human MS4A1 Antibody (Non-glycosylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-LC066 | PE-A*02:01/Human CD20 (SLFLGILSV) MHC Tetramer | FCM | |
MHC-LC067 | APC-A*02:01/Human CD20 (SLFLGILSV) MHC Tetramer | FCM | |
MHC-LC068 | BV421-A*02:01/Human CD20 (SLFLGILSV) MHC Tetramer | FCM | |
MHC-LC4347 | PE-B*07:02/Human MS4A1 (RPKSNIVLL) MHC Tetramer | FCM |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1751CQ | Mouse Anti-MS4A1 Recombinant Antibody (clone CBLS-211) | Neut, FuncS | Mouse IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2295 | Hi-Affi™ Rabbit Anti-MS4A1 Recombinant Antibody (clone DS2295AB) | IHC-Fr, IHC-P | Rabbit IgG |
MOR-4024 | Hi-Affi™ Rabbit Anti-MS4A1 Recombinant Antibody (clone SI88DS) | FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-772 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Ocrelizumab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | ADCC enhanced antibody |
AFC-TAB-016 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Rituximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-028 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Ofatumumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
AFC-TAB-207 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Ublituximab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | ADCC enhanced antibody |
AFC-TAB-771 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Ocaratuzumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-1586-FY-F(E) | Mouse Anti-MS4A1 Recombinant Antibody (clone CD20-7); scFv Fragment | ELISA, Cyt | Mouse scFv |
HPAB-1587-FY-F(E) | Human Anti-MS4A1 Recombinant Antibody (clone huCD20-7); scFv Fragment | ELISA, Cyt | Humanized scFv |
HPAB-1588-FY-F(E) | Human Anti-MS4A1 Recombinant Antibody (clone 3c5); scFv Fragment | ELISA | Human scFv |
HPAB-1775-FY-F(E) | Mouse Anti-MS4A1 Recombinant Antibody; Fab Fragment (HPAB-1775-FY-F(E)) | ELISA, Activ | Mouse Fab |
HPAB-1776-FY-F(E) | Mouse Anti-MS4A1 Recombinant Antibody; Fab Fragment (HPAB-1776-FY-F(E)) | ELISA, Activ | Mouse Fab |
There are currently no Customer reviews or questions for HPAB-N0181-YC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.